Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Be SMART NIS, Moderate to Servere Asthma Patient Observation

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: August 9, 2007
Last updated: March 26, 2009
Last verified: March 2009
Screen for moderate to severe asthma patients with suboptimal asthma control (as defined by GINA-Guidelines). Document current asthma control status. Re-evaluate asthma therapy and document new therapy if applicable.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Be SMART NIS, Moderate to Servere Asthma Patient Observation

Further study details as provided by AstraZeneca:

Estimated Enrollment: 900

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Moderate to severe asthma with suboptimal control

Exclusion Criteria:

  • Intermittent or mild asthma, patient with good asthma control
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00514787

Research Site
Vienna, Austria
Sponsors and Collaborators
Study Chair: Wolfgang Pohl, PHD Executive Board OGP (Austria Society of Pneumology
  More Information Identifier: NCT00514787     History of Changes
Other Study ID Numbers: NIS-RAT-SYM-2007/1 
Study First Received: August 9, 2007
Last Updated: March 26, 2009
Health Authority: Austria: Agency for Health and Food Safety

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on October 21, 2016